
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.
What Happened: According to Reuters, the Trump administration made a deal with drugmaker Merck KGaA (OTC:MKGAF) to dramatically cut the cost of IVF medications. Under the agreement, Merck's fertility drugs — like Gonal-f, Ovidrel, and Cetrotide — will be heavily discounted when used for IVF treatment, saving patients approximately $2,200 per treatment cycle.